Model-based drug development: the road to quantitative pharmacology. - Wikidata - awgldk - TriplyDB

Model-based drug development: the road to quantitative pharmacology.

Model-based drug development: the road to quantitative pharmacology.

http://www.wikidata.org/entity/Q34537529

about

Antiretroviral pharmacology in mucosal tissues Agent-based modeling: a systematic assessment of use cases and requirements for enhancing pharmaceutical research and development productivity Comparisons of Analysis Methods for Proof-of-Concept Trials.Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide.OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis.Globalization of quantitative pharmacology: first international symposium of quantitative pharmacology in drug development and regulation.Concepts and challenges in quantitative pharmacology and model-based drug development.Bayesian quantitative disease-drug-trial models for Parkinson's disease to guide early drug development.Exposure-response model for sibutramine and placebo: suggestion for application to long-term weight-control drug development Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis.Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn Disease Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings.Effects of pharmaceuticals and other active chemicals at biological targets: mechanisms, interactions, and integration into PB-PK/PD models.The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy.Next-generation model-based drug discovery and development: quantitative and systems pharmacology.Clinical trial simulation: a review.ASCPT Task Force for advancing pharmacometrics and integration into drug development.Probabilistic risk analysis: improving early drug development decision making.Quantitative clinical pharmacology is transforming drug regulation.Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?Role of modelling and simulation: a European regulatory perspective.The current role of model-based drug development.Translational PK-PD modeling in pain.Approaches to in vitro tissue regeneration with application for human disease modeling and drug development.Pharmacologic considerations in use and development of antituberculosis drugs.Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients.In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation.The role of pharmacokinetic and pharmacokinetic/pharmacodynamic modeling in drug discovery and development.Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer Pharmacometrics 2020.Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry.Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success.Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity.Assessment of the Efficacy of New Anti-Tuberculosis Drugs.Model based design and analysis of phase II HIV-1 trials.Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm.Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models.

P2860

Q27014675-35BC4971-CB95-4A24-A06C-52D2EA1659F5 Q27028010-A48E8C3E-5C30-4BCE-9628-31B206E2C4E4 Q30537763-E964DB06-7B8C-4685-B782-759232A510BE Q33524423-338EF44D-31D9-4B76-81C3-8EFF2544F3B5 Q33809839-9806D66F-EAF7-4494-9515-8B7FFEA9DF9F Q34475498-9FE99BA6-3221-4A12-8810-FA2DE7969765 Q34779737-29F0C302-AF37-41B4-870E-8FB06DF31346 Q34878168-2556C162-4149-4DDD-8365-D9D60198DCA7 Q35595794-6FD257EA-FCB4-48E6-B31F-6F6B2FE70860 Q36068367-4B3C08CA-40A6-4F6E-AC4A-8E5E4C6F43CE Q36094941-AC14C763-6F74-45C7-90FD-77A4B9B2019C Q36364005-8A90C18F-FD04-4029-AE47-E94CFD86EE1F Q36625233-3996E3D7-3090-434C-AC4E-229292ECD009 Q36828605-A7043A17-7AE9-4019-94E8-C98EFD063B95 Q37149100-811BF58B-A580-4B28-AE22-83A46E13F2BD Q37521097-C8C10B48-6D38-4A78-B4D6-2AA579B14886 Q37521422-793E6173-7725-41FA-9629-D7D7EF1E55D0 Q37763515-B7424A7E-4440-4D0A-AB58-D1BCDBD4232D Q37770955-0C51AC14-A7C3-4E2F-8BD1-DF6C86E7DB40 Q37774550-1C620552-8815-4C00-B9A5-E8991AE11C2B Q37800008-4E556EEC-01F1-4238-B099-4EDC124ABBC5 Q37803359-FFE0464B-ED70-4865-B1AE-3C383FA2DAC4 Q37834445-576E2AC0-5D44-4959-B23A-957F91DE41D8 Q37976876-319F7790-F0A1-4988-A8BE-7913346A7880 Q38028538-38139DA5-B731-4F76-BBA1-764AC5F05502 Q38063813-529B7C47-1EEE-440D-9A9C-B3F81FBB783B Q38209078-0E52B83F-16D7-4F6A-9A5D-C3876145B895 Q38252559-5046AE85-F4F6-4E38-A384-544B91B0CA6D Q38611990-8BA8B75A-DFF6-4707-9AEB-0DE5A9D3E280 Q39246575-4CF9FEDC-D367-4CE5-8710-F225BD443647 Q39769308-E65DB5C8-FE7C-4EF3-871A-5FFB88EEAF0E Q39803248-854EA96C-11C7-4D8B-B6F0-2875C9909AD5 Q39828337-8C07AFC3-DB59-450E-B952-72860ADD756F Q39828343-C2D57E69-7951-4E48-8E56-B6BCC342C78B Q39828349-27F5549A-61DC-4F1B-ACA6-F61135EEEAFC Q39959170-948458F4-A77B-43C8-9591-3DDE74C276CA Q41572870-AF88AD24-A736-424F-9FAA-444C91870FEB Q42284705-FACF1790-DA9B-468C-8F9F-70D990277F5E Q42359116-57BCF517-C7E4-4B27-9F7C-D803094CC050 Q42546762-B8D05DD7-5969-4315-8F83-AD1D9091835F

P2860

Model-based drug development: the road to quantitative pharmacology.

http://www.wikidata.org/entity/Q34537529

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Model-based drug development: the road to quantitative pharmacology.

@ast

Model-based drug development: the road to quantitative pharmacology.

@en

Model-based drug development: the road to quantitative pharmacology.

@nl

type

label

Model-based drug development: the road to quantitative pharmacology.

@ast

Model-based drug development: the road to quantitative pharmacology.

@en

Model-based drug development: the road to quantitative pharmacology.

@nl

prefLabel

Model-based drug development: the road to quantitative pharmacology.

@ast

Model-based drug development: the road to quantitative pharmacology.

@en

Model-based drug development: the road to quantitative pharmacology.

@nl

P1433

Q34537529-9F54C04C-5866-4F94-84BA-E50F5670F7A2

P1476

Q34537529-C893EC1F-3C13-4B22-9FA9-FE4476D243B4

P2093

Q34537529-2487CCEE-6F73-4119-8D09-11F5EA8AD57F

Q34537529-4673E87A-12AA-4C86-82EB-6CB4A3923151

Q34537529-7C1F840D-9550-4617-8E4F-A95B6E1D41B6

Q34537529-81FB4466-737F-443C-8DE0-91E71E7AAC77

Q34537529-A8197CF8-C347-4112-B482-2EA9E74F848C

Q34537529-ADC54A70-D22A-4C91-9DD7-B14BE5DF33CC

Q34537529-D38101B2-5969-4FC3-A2EA-DC97FEC64D34

P2888

Q34537529-A33958FC-B368-4102-A613-C54881D85308

P304

Q34537529-DF4DBCF0-C958-4FC4-B9A5-76B407D5DB24

P31

Q34537529-A22EFE8E-424D-408D-B5F9-69A6B1CD5B72

P356

Q34537529-1D69A04F-D1BC-47EC-8216-B95A6E760506

P433

Q34537529-E568FFBD-86FD-490C-B977-5FB2FE98F6EB

P478

Q34537529-CF910653-8ABD-49F8-A169-C0859DE23B76

P577

Q34537529-8D14E060-068C-4004-B53C-598627F23504

P6179

Q34537529-FD603B54-491C-45A2-BE71-A2C2AA0D44C0

P698

Q34537529-583167A6-9B1C-40F9-914F-6F03DD6CF954

P921

Q34537529-55FCF0D6-228A-42D8-B38F-C6AC0D16FD80

P356

S10928-006-9010-8

P1433

Journal of Pharmacokinetics and Pharmacodynamics

P1476

Model-based drug development: the road to quantitative pharmacology.

@en

P2093

Lan Ni

http://www.w3.org/2001/XMLSchema#string

Liping Zhang

http://www.w3.org/2001/XMLSchema#string

Richard Peck

http://www.w3.org/2001/XMLSchema#string

S Thomas Forgue

http://www.w3.org/2001/XMLSchema#string

Sandra R B Allerheiligen

http://www.w3.org/2001/XMLSchema#string

Sophie Callies

http://www.w3.org/2001/XMLSchema#string

Vikram Sinha

http://www.w3.org/2001/XMLSchema#string

P2888

s10928-006-9010-8

P304

369-393

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10928-006-9010-8

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2006-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1035357317

http://www.w3.org/2001/XMLSchema#string

P698

16770528

http://www.w3.org/2001/XMLSchema#string

P921